Best Practice & Research Clinical Rheumatology
Volume 22, Issue 2 , Pages 239-252 , April 2008

The role of resident synovial cells in destructive arthritis

References 

  1. Lee DM, Kiener HP, Agarwal SK, et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science. 2007;315:1006–1010
  2. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. The New England Journal of Medicine. 2000;343:1594–1602
  3. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis and Rheumatism. 2004;50:1051–1065
  4. Cohen G, Gossec L, Dougados M, et al. Radiological damage in patients with rheumatoid arthritis on sustained remission. Annals of the Rheumatic Diseases. 2007;66:358–363
  5. Fassbender HG. Histomorphological basis of articular cartilage destruction in rheumatoid arthritis. Collagen and Related Research. 1983;3:141–155
  6. Fassbender HG. What destroys the joint in rheumatoid arthritis?. Archives of Orthopaedic and Trauma Surgery. 1998;117:2–7
  7. Lafyatis R, Remmers EF, Roberts AB, et al. Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. The Journal of Clinical Investigation. 1989;83:1267–1276
  8. Gay S, Gay RE, Koopman WJ. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction?. Annals of the Rheumatic Diseases. 1993;52(Suppl. 1):S39–S47
  9. Muller-Ladner U, Kriegsmann J, Franklin BN, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. American Journal of Pathology. 1996;149:1607–1615
  10. Neidhart M, Seemayer CA, Hummel KM, et al. Functional characterization of adherent synovial fluid cells in rheumatoid arthritis: destructive potential in vitro and in vivo. Arthritis and Rheumatism. 2003;48:1873–1880
  11. Tolboom TC, Pieterman E, van der Laan WH, et al. Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Annals of the Rheumatic Diseases. 2002;61:975–980
  12. Seemayer CA, Kuchen S, Kuenzler P, et al. Cartilage destruction mediated by synovial fibroblasts does not depend on proliferation in rheumatoid arthritis. American Journal of Pathology. 2003;162:1549–1557
  13. Aidinis V, Carninci P, Armaka M, et al. Cytoskeletal rearrangements in synovial fibroblasts as a novel pathophysiological determinant of modeled rheumatoid arthritis. PLoS Genetics. 2005;1:e48
  14. Pawlak G, Helfman DM. Cytoskeletal changes in cell transformation and tumorigenesis. Current Opinion in Genetics and Development. 2001;11:41–47
  15. Trabandt A, Aicher WK, Gay RE, et al. Expression of the collagenolytic and Ras-induced cysteine proteinase cathepsin L and proliferation-associated oncogenes in synovial cells of MRL/I mice and patients with rheumatoid arthritis. Matrix. 1990;10:349–361
  16. Pap T, Nawrath M, Heinrich J, et al. Cooperation of Ras- and c-Myc-dependent pathways in regulating the growth and invasiveness of synovial fibroblasts in rheumatoid arthritis. Arthritis and Rheumatism. 2004;50:2794–2802
  17. Kinne RW, Boehm S, Iftner T, et al. Synovial fibroblast-like cells strongly express jun-B and C-fos proto-oncogenes in rheumatoid- and osteoarthritis. Scandinavian Journal of Rheumatology Supplement. 1995;101:121–125
  18. Neidhart M, Zaucke F, von Knoch R, et al. Galectin-3 is induced in rheumatoid arthritis synovial fibroblasts after adhesion to cartilage oligomeric matrix protein. Annals of the Rheumatic Diseases. 2005;64:419–424
  19. Baier A, Meineckel I, Gay S, Pap T. Apoptosis in rheumatoid arthritis. Current Opinion in Rheumatology. 2003;15:274–279
  20. Perlman H, Georganas C, Pagliari LJ, et al. Bcl-2 expression in synovial fibroblasts is essential for maintaining mitochondrial homeostasis and cell viability. Journal of Immunology. 2000;164:5227–5235
  21. Busteed S, Bennett MW, Molloy C, et al. Bcl-x(L) expression in vivo in rheumatoid synovium. Clinical Rheumatology. 2006;25:789–793
  22. Liu XH, Yu EZ, Li YY, Kagan E. HIF-1alpha has an anti-apoptotic effect in human airway epithelium that is mediated via Mcl-1 gene expression. Journal of Cellular Biochemistry. 2006;97:755–765
  23. Kurowska M, Rudnicka W, Kontny E, et al. Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2. Journal of Immunology. 2002;169:1760–1767
  24. Scatizzi JC, Bickel E, Hutcheson J, et al. Bim deficiency leads to exacerbation and prolongation of joint inflammation in experimental arthritis. Arthritis and Rheumatism. 2006;54:3182–3193
  25. Asahara H, Hasumuna T, Kobata T, et al. Expression of Fas antigen and Fas ligand in the rheumatoid synovial tissue. Clinical Immunology and Immunopathology. 1996;81:27–34
  26. Firestein GS, Yeo M, Zvaifler NJ. Apoptosis in rheumatoid arthritis synovium. The Journal of Clinical Investigation. 1995;96:1631–1638
  27. Nakajima T, Aono H, Hasunuma T, et al. Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis and Rheumatism. 1995;38:485–491
  28. Sugiyama M, Tsukazaki T, Yonekura A, et al. Localisation of apoptosis and expression of apoptosis related proteins in the synovium of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 1996;55:442–449
  29. Meinecke I, Cinski A, Baier A, et al. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:5073–5078
  30. Palao G, Santiago B, Galindo M, et al. Down-regulation of FLIP sensitizes rheumatoid synovial fibroblasts to Fas-mediated apoptosis. Arthritis and Rheumatism. 2004;50:2803–2810
  31. Franz JK, Pap T, Hummel KM, et al. Expression of sentrin, a novel antiapoptotic molecule, at sites of synovial invasion in rheumatoid arthritis. Arthritis and Rheumatism. 2000;43:599–607
  32. Schedel J, Gay RE, Kuenzler P, et al. FLICE-inhibitory protein expression in synovial fibroblasts and at sites of cartilage and bone erosion in rheumatoid arthritis. Arthritis and Rheumatism. 2002;46:1512–1518
  33. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190–195
  34. Amano T, Yamasaki S, Yagishita N, et al. Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy. Genes and Development. 2003;17:2436–2449
  35. Toh ML, Marotte H, Blond JL, et al. Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment. Arthritis and Rheumatism. 2006;54:2109–2118
  36. Firestein GS, Nguyen K, Aupperle KR, et al. Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. American Journal of Pathology. 1996;149:2143–2151
  37. Seemayer CA, Kuchen S, Neidhart M, et al. p53 in rheumatoid arthritis synovial fibroblasts at sites of invasion. Annals of the Rheumatic Diseases. 2003;62:1139–1144
  38. Firestein GS, Echeverri F, Yeo M, et al. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proceedings of the National Academy of Sciences of the United States of America. 1997;94:10895–10900
  39. Aupperle KR, Boyle DL, Hendrix M, et al. Regulation of synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene. American Journal of Pathology. 1998;152:1091–1098
  40. Cha HS, Rosengren S, Boyle DL, Firestein GS. PUMA regulation and proapoptotic effects in fibroblast-like synoviocytes. Arthritis and Rheumatism. 2006;54:587–592
  41. Pap T, Aupperle KR, Gay S, et al. Invasiveness of synovial fibroblasts is regulated by p53 in the SCID mouse in vivo model of cartilage invasion. Arthritis and Rheumatism. 2001;44:676–681
  42. Perlman H, Bradley K, Liu H, et al. IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts. Journal of Immunology. 2003;170:838–845
  43. Pap T, Franz JK, Hummel KM, et al. Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Research. 2000;2:59–64
  44. di Giovine FS, Bailly S, Bootman J, et al. Absence of lentiviral and human T cell leukemia viral sequences in patients with rheumatoid arthritis. Arthritis and Rheumatism. 1994;37:349–358
  45. Seemayer CA, Kolb SA, Neidhart M, et al. Absence of inducible retroviruses from synovial fibroblasts and synovial fluid cells of patients with rheumatoid arthritis. Arthritis and Rheumatism. 2002;46:2811–2813
  46. Neidhart M, Rethage J, Kuchen S, et al. Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: association with genomic DNA hypomethylation and influence on gene expression. Arthritis and Rheumatism. 2000;43:2634–2647
  47. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nature Reviews. Immunology. 2007;7:429–442
  48. Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Research. 2002;4(Suppl. 3):S81–S90
  49. Mapp PI, Grootveld MC, Blake DR. Hypoxia, oxidative stress and rheumatoid arthritis. British Medical Bulletin. 1995;51:419–436
  50. Distler JH, Jungel A, Huber LC, et al. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:2892–2897
  51. Berckmans RJ, Nieuwland R, Tak PP, et al. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis and Rheumatism. 2002;46:2857–2866
  52. Brentano F, Schorr O, Gay RE, et al. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis and Rheumatism. 2005;52:2656–2665
  53. Pierer M, Rethage J, Seibl R, et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. Journal of Immunology. 2004;172:1256–1265
  54. Seibl R, Birchler T, Loeliger S, et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. American Journal of Pathology. 2003;162:1221–1227
  55. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. Journal of Immunology. 2001;167:2887–2894
  56. Kariko K, Ni H, Capodici J. mRNA is an endogenous ligand for Toll-like receptor 3. The Journal of Biological Chemistry. 2004;279:12542–12550
  57. Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets?. Arthritis and Rheumatism. 2005;52:710–721
  58. Tak PP. Chemokine inhibition in inflammatory arthritis. Best Practice and Research. Clinical Rheumatology. 2006;20:929–939
  59. Koch AE, Kunkel SL, Harlow LA, et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. The Journal of Clinical Investigation. 1994;94:1012–1018
  60. Villiger PM, Terkeltaub R, Lotz M. Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. Journal of Immunology. 1992;149:722–727
  61. Berckmans RJ, Nieuwland R, Kraan MC, et al. Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Research and Therapy. 2005;7:R536–R544
  62. Rathanaswami P, Hachicha M, Sadick M, et al. Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. The Journal of Biological Chemistry. 1993;268:5834–5839
  63. Hitchon C, Wong K, Ma G, et al. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis and Rheumatism. 2002;46:2587–2597
  64. Nanki T, Nagasaka K, Hayashida K, et al. Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Journal of Immunology. 2001;167:5381–5385
  65. Kraan MC, Patel DD, Haringman JJ, et al. The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8). Arthritis Research. 2001;3:65–71
  66. Koch AE, Kunkel SL, Burrows JC, et al. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. Journal of Immunology. 1991;147:2187–2195
  67. Cho ML, Ju JH, Kim HR, et al. Toll-like receptor 2 ligand mediates the upregulation of angiogenic factor, vascular endothelial growth factor and interleukin-8/CXCL8 in human rheumatoid synovial fibroblasts. Immunology Letters. 2007;108:121–128
  68. Franz JK, Kolb SA, Hummel KM, et al. Interleukin-16, produced by synovial fibroblasts, mediates chemoattraction for CD4+T lymphocytes in rheumatoid arthritis. European Journal of Immunology. 1998;28:2661–2671
  69. Harada S, Yamamura M, Okamoto H, et al. Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis and Rheumatism. 1999;42:1508–1516
  70. Ohata J, Zvaifler NJ, Nishio M, et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. Journal of Immunology. 2005;174:864–870
  71. Bucala R, Ritchlin C, Winchester R, Cerami A. Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. The Journal of Experimental Medicine. 1991;173:569–574
  72. Lindhout E, van Eijk M, van Pel M, et al. Fibroblast-like synoviocytes from rheumatoid arthritis patients have intrinsic properties of follicular dendritic cells. Journal of Immunology. 1999;162:5949–5956
  73. Salmon M, Scheel-Toellner D, Huissoon AP, et al. Inhibition of T cell apoptosis in the rheumatoid synovium. The Journal of Clinical Investigation. 1997;99:439–446
  74. Boots AM, Wimmers-Bertens AJ, Rijnders AW. Antigen-presenting capacity of rheumatoid synovial fibroblasts. Immunology. 1994;82:268–274
  75. Corrigall VM, Solau-Gervais E, Panayi GS. Lack of CD80 expression by fibroblast-like synoviocytes leading to anergy in T lymphocytes. Arthritis and Rheumatism. 2000;43:1606–1615
  76. Tran CN, Davis MJ, Tesmer LA, et al. Presentation of arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes. Arthritis and Rheumatism. 2007;56:1497–1506
  77. Jackson JR, Minton JA, Ho ML, et al. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. The Journal of Rheumatology. 1997;24:1253–1259
  78. Cho CS, Cho ML, Min SY, et al. CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor. Journal of Immunology. 2000;164:5055–5061
  79. Fava RA, Olsen NJ, Spencer-Green G, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. The Journal of Experimental Medicine. 1994;180:341–346
  80. Koch AE. The role of angiogenesis in rheumatoid arthritis: recent developments. Annals of the Rheumatic Diseases. 2000;59(Suppl. 1):i65–i71
  81. Bodolay E, Koch AE, Kim J, et al. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. Journal of Cellular and Molecular Medicine. 2002;6:357–376
  82. Page G, Miossec P. RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis and Rheumatism. 2005;52:2307–2312
  83. Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis and Rheumatism. 2000;43:250–258
  84. Kim KW, Cho ML, Lee SH, et al. Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation. Immunology Letters. 2007;110:54–64
  85. Shigeyama Y, Pap T, Kunzler P, et al. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis and Rheumatism. 2000;43:2523–2530
  86. Green MJ, Gough AK, Devlin J, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford). 2003;42:83–88
  87. Kobayashi A, Naito S, Enomoto H, et al. Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Archives of Pathology & Laboratory Medicine. 2007;131:563–570
  88. Yamanaka H, Matsuda Y, Tanaka M, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis and Rheumatism. 2000;43:852–858
  89. Ates A, Turkcapar N, Olmez U, et al. Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers. Rheumatology International. 2007;27:715–722
  90. Gravallese EM, Darling JM, Ladd AL, et al. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis and Rheumatism. 1991;34:1076–1084
  91. Cha HS, Ahn KS, Jeon CH, et al. Influence of hypoxia on the expression of matrix metalloproteinase-1, -3 and tissue inhibitor of metalloproteinase-1 in rheumatoid synovial fibroblasts. Clinical and Experimental Rheumatology. 2003;21:593–598
  92. Kyburz D, Rethage J, Seibl R, et al. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Arthritis and Rheumatism. 2003;48:642–650
  93. Burger D, Rezzonico R, Li JM, et al. Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: involvement of membrane-associated cytokines. Arthritis and Rheumatism. 1998;41:1748–1759
  94. Rutkauskaite E, Zacharias W, Schedel J, et al. Ribozymes that inhibit the production of matrix metalloproteinase 1 reduce the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis and Rheumatism. 2004;50:1448–1456
  95. Cunnane G, FitzGerald O, Hummel KM, et al. Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. Rheumatology (Oxford). 1999;38:34–42
  96. Schedel J, Seemayer CA, Pap T, et al. Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis. Gene Therapy. 2004;11:1040–1047
  97. Hou WS, Li Z, Gordon RE, et al. Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation. American Journal of Pathology. 2001;159:2167–2177
  98. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annual Review of Immunology. 2001;19:163–196
  99. Ospelt C, Neidhart M, Gay RE, et al. Gene analysis for exploring the effects of drugs in rheumatoid arthritis. Arthritis and Rheumatism. 2005;52:2248–2256
  100. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms?. Trends in Cell Biology. 2007;17:118–126
  101. Bartel DP. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell. 2004;116:281–297
  102. Taganov KD, Boldin MP, Baltimore D. MicroRNAs and Immunity: tiny players in a big field. Immunity. 2007;26:133–137
  103. Chen C-Z. MicroRNAs as Oncogenes and Tumor Suppressors. The New England Journal of Medicine. 2005;353:1768–1771

PII: S1521-6942(08)00005-3

doi: 10.1016/j.berh.2008.01.004

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 2 , Pages 239-252 , April 2008

Article Tools

* Image Usage & Resolution